Osimertinib Recruiting Phase 2 Trials for Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03667820Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
NCT03784599T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
NCT02811354Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA
NCT03586453Osimertinib In EGFR Mutant Lung Cancer
NCT03944772Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
NCT03392246A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
NCT03865511MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib
NCT02841579Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M
NCT03460275Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer
NCT03394118TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using BALF, Plasma or Pleural Effusion
NCT02856893Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
NCT03434418A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations